Sanofi temporarily stopped recruiting new COVID-19 patients for two clinical trials on hydroxychloroquine and will no longer supply the anti-malaria drug to treat COVID-19 until concerns about safety are cleared up.
Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported.
France, Italy and Belgium acted to halt the use of hydroxychloroquine to treat patients suffering from COVID-19 amid questions about the safety of the generic anti-malaria drug.
Questions over the efficacy and safety of hydroxychloroquine continue to be raised following the World Health Organization’s decision to temporarily halt a study of the malaria drug as a potential treatment for COVID-19.
The malaria drug hydroxychloroquine – which U.S. President Donald Trump says he has been taking – is tied to increased risk of death in COVID-19 patients, according to a study published in the medical journal Lancet.
Healthcare workers in Britain and Thailand started taking part in a trial to determine whether two anti-malarial drugs can prevent COVID-19, including one that U.S. President Donald Trump says he has been taking.
Patients given the malaria drug touted by President Donald Trump as a potential treatment for COVID-19 did not improve significantly over those who did not, according to two new studies published in the medical journal BMJ .
At least 10 different drug compounds ranging from cancer therapies to antipsychotics and antihistamines may be effective at preventing the new coronavirus from multiplying in the body, according to a multidisciplinary study conducted by a team of scientists in the United States and France.
India shipped 50 million tablets of hydroxychloroquine to the United States, an Indian source with direct knowledge of the exports said, although U.S. regulators warned the anti-malarial drug may have harmful side effects in the treatment of COVID-19.
More drugs are being assessed as potential treatments against the pandemic as the battle against COVID-19 continues. Researchers in New York are seeking to determine if the active ingredient in an over-the-counter heartburn medication will have any impact on the disease.